D-1 Type of Dopamine Autoreceptors Are Not Involved in the Regulation of Dopamine Synthesis in the Striatum

Hiroshi WATANABE, Hiroshi SUDA, Shun-ichi SEKIHARA and Yasuyuki NOMURA

Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, Toyama 930-01, Japan

Accepted December 24, 1986

Abstract—To clarify if dopamine (DA) synthesis is regulated by D-1 DA receptors located on dopaminergic nerve terminals in the striatum, we investigated effects of D-1 DA receptor agonist and antagonist on striatal 3,4-dihydroxyphenylalanine (DOPA) accumulation induced by \( r \)-butyrolactone in mice treated with an amino acid decarboxylase inhibitor. SKF 38393, a D-1 agonist, did not affect DOPA accumulation, whereas apomorphine that stimulates both D-1 and D-2 receptors inhibited the accumulation. SCH 23390, a D-1 antagonist, did not antagonize apomorphine-induced inhibition of DOPA accumulation, while YM-09151-2, a D-2 antagonist, reversed it. These results suggest that D-1 type of DA autoreceptors is not involved in the inhibition of in vivo DA synthesis.

Selective stimulation of dopamine (DA) autoreceptors located on dopaminergic nerve terminals in the striatum modulates the release of DA in vitro (1, 2) and DA synthesis in vitro and in vivo (3–5). Electrical stimulation- or depolarization-induced release of \( ^3 \)H-DA is inhibited by treatment with apomorphine and a D-2 receptor agonist, LY 141865, and this inhibition is antagonized by a D-2 receptor antagonist, (−)-sulpiride, while the release was not suppressed by the D-1 receptor agonist SKF 38393 (6, 7). These results suggest that release-inhibiting DA autoreceptors can be classified as the D-2 type (linked or not linked to an inhibition of adenylate cyclase) (8).

It is not known, however, whether those receptors are identical to autoreceptors regulating DA synthesis in nerve endings, but recent data suggest that they are distinct because doses of apomorphine which inhibit the synthesis of DA have no effect on its release in striatal slices (3). Further, no data have been reported about whether the D-1 type of autoreceptors is involved in the regulation of DA synthesis or not. Hence, to clarify if DA synthesis in the striatum is regulated by a mediation of the D-1 type of DA autoreceptors, we investigated effects of D-1 receptor agonist and antagonist on striatal 3,4-dihydroxyphenylalanine (DOPA) accumulation, which reflects DA synthesis, induced by \( r \)-butyrolactone in mice treated with an amino acid decarboxylase inhibitor and compared them with those of D-2 receptor related agents.

Adult male albino mice weighing 22–30 g (ddY strain, Shizuoka Laboratory Animal Center, Shizuoka) were used. Mice were injected with SKF 38393 or apomorphine, 10 min later with \( r \)-butyrolactone (750 mg/kg, i.p.), and a further 5 min later with 3-hydroxybenzylhydrazine (100 mg/kg, i.p.) to inhibit aromatic amino acid decarboxylase. Mice were killed by decapitation 30 min after the treatment with the decarboxylase inhibitor. The striata were dissected out after removal of the brain, homogenized in 1 ml of 0.25 N perchloric acid containing 0.2 mM EDTA and 40 ng of 3,4-dihydroxybenzylamine as an internal standard. DOPA and catecholamines were extracted with alumina and assayed using HPLC with electrochemical detection (9, 10).

Apomorphine hydrochloride (Dainippon Seiyaku), SKF 38393 (1-phenyl-2,3,4,5-tetra-
hydro-(1H)-3-benzazepine-7,8-diol hydrochloride; Research Biochemicals Inc.) and 3-hydroxybenzylhydrazine dihydrochloride (Sigma Chemical Co.) were dissolved in sterile saline containing 0.05% ascorbic acid. Haloperidol (Janssen), (+)-sulpiride (Fujisawa Yakuhin), YM 09151-2 (cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methyl-aminobenzamide; Yamanouchi Seiyaku) and SCH 23390 (R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol-maleate; Schering Corp.) were dissolved in saline containing 0.1% tartaric acid. γ-Butyrolactone (Tokyo Kasei) was dissolved in physiological saline. All doses refer to the salt except for 3-hydroxybenzylhydrazine. Data were analyzed using one-way analysis of variance with Duncan’s multiple comparison test (11).

γ-Butyrolactone (750 mg/kg, i.p.) produced a rise in striatal DOPA levels to nearly 200% above 3-hydroxybenzylhydrazine treated values. Pretreatment of animals with SKF 38393 (0.3-30 mg/kg, s.c.) caused no changes in DOPA accumulation induced by γ-butyrolactone, whereas apomorphine (0.03–0.3 mg/kg, s.c.) inhibited it in a dose-dependent manner (Table 1).

The inhibitory effect of apomorphine was not affected by pretreatment with SCH 23390 (0.025–2.5 mg/kg, s.c.), whereas it was reversed by haloperidol (0.05 mg/kg, s.c.), (+)-sulpiride (100 mg/kg, s.c.) and YM-09151-2 (0.005 mg/kg, s.c.) (Table 2).

The previous findings that SKF 38393 affects neither DA disappearance following α-methyl-p-tyrosine treatment (12) nor striatal DOPA levels after an amino acid decarboxylase inhibitor (13, 14) suggest that the D-1 type of autonomic or postsynaptic DA receptors are not involved in the regulation of DA turnover and synthesis. The present results have shown that autoreceptors regulating DA synthesis in the striatum are not stimulated by the D-1 receptor agonist SKF 38393 (15), while they are stimulated by apomorphine; the stimulatory effect of apomorphine is antagonized by D-2 receptor antagonists, (+)-sulpiride (8) and YM-09151-2 (16), but not by a D-1 receptor antagonist (17, 18). It has been shown that DA synthesis in rat striatal slices which do not contain a striatonigral feedback loop is inhibited by apomorphine or the D-2 receptor agonist LY 141865 (3, 19), and this inhibition is antagonized by an addition of haloperidol in a superfusion system (3). In vivo DA synthesis increased by γ-butyrolactone is inhibited by D-2 receptor agonists, lisuride and bromocriptine, and the inhibition is antagonized by pretreatment with (+)-sulpiride in the rat striatum (20). Thus, the present results support the neurochemical data suggesting that DA autoreceptors which

### Table 1. Effects of SKF 38393 and apomorphine on DOPA accumulation induced by γ-butyrolactone in the striatum of the mouse treated with an amino acid decarboxylase inhibitor

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose (mg/kg)</th>
<th>N</th>
<th>DOPA (µg/g wet tissue)</th>
<th>% of control</th>
</tr>
</thead>
<tbody>
<tr>
<td>γ-Butyrolactone control</td>
<td>12</td>
<td></td>
<td>4.99±0.16</td>
<td>100</td>
</tr>
<tr>
<td>SKF 38393</td>
<td>0.3</td>
<td>5</td>
<td>4.82±0.31</td>
<td>96.6</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>5</td>
<td>5.45±0.24</td>
<td>109.2</td>
</tr>
<tr>
<td></td>
<td>3.0</td>
<td>5</td>
<td>5.70±0.39</td>
<td>114.2</td>
</tr>
<tr>
<td></td>
<td>10.0</td>
<td>5</td>
<td>4.61±0.42</td>
<td>92.4</td>
</tr>
<tr>
<td></td>
<td>30.0</td>
<td>5</td>
<td>4.96±0.39</td>
<td>99.4</td>
</tr>
<tr>
<td>Apomorphine</td>
<td>0.03</td>
<td>5</td>
<td>4.67±0.27</td>
<td>93.6</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>5</td>
<td>3.49±0.16**</td>
<td>78.0</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>5</td>
<td>2.36±0.30**</td>
<td>47.3</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>5</td>
<td>1.77±0.14**</td>
<td>37.9</td>
</tr>
</tbody>
</table>

Each value represents the mean±S.E.M. DOPA levels after 3-hydroxybenzylhydrazine treatment were 1.61±0.08 µg/g (N=12). N=number of experiments. **P<0.01, compared with the γ-butyrolactone control.
Table 2. Effects of D-1 and D-2 receptor antagonists on apomorphine-induced decrease in striatal DOPA accumulation following the treatment with γ-butyrolactone plus 3-hydroxybenzylhydrazine

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose (mg/kg)</th>
<th>N</th>
<th>DOPA (µg/g wet tissue)</th>
<th>% of control</th>
</tr>
</thead>
<tbody>
<tr>
<td>γ-Butyrolactone control</td>
<td>0.1</td>
<td>12</td>
<td>4.44±0.14</td>
<td>100</td>
</tr>
<tr>
<td>Apomorphine</td>
<td>0.1</td>
<td>12</td>
<td>2.61±0.07**</td>
<td>58.8</td>
</tr>
<tr>
<td>Apomorphine +SCH 23390</td>
<td>0.025</td>
<td>6</td>
<td>2.69±0.15**</td>
<td>60.6</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>6</td>
<td>2.96±0.42**</td>
<td>68.7</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>6</td>
<td>2.85±0.14**</td>
<td>59.7</td>
</tr>
<tr>
<td>+Haloperidol</td>
<td>0.05</td>
<td>6</td>
<td>4.30±0.24</td>
<td>96.8</td>
</tr>
<tr>
<td>(+)-Sulpiride</td>
<td>100</td>
<td>6</td>
<td>4.11±0.10</td>
<td>92.6</td>
</tr>
<tr>
<td>+YM 09151-2</td>
<td>0.001</td>
<td>6</td>
<td>2.41±0.27**</td>
<td>54.3</td>
</tr>
<tr>
<td></td>
<td>0.005</td>
<td>6</td>
<td>4.64±0.87</td>
<td>104.6</td>
</tr>
</tbody>
</table>

D-1 or D-2 receptor antagonist was administered 20 min prior to apomorphine (65 min before sacrifice). Each value represents the mean±S.E.M. DOPA levels after 3-hydroxybenzylhydrazine treatment were 1.49±0.06 µg/g (N=12). N=number of experiments. **P<0.01, compared with the γ-butyrolactone control.

regulate the DA synthesis in the striatum are not D-1 but D-2 type. On the other hand, it has been reported that evoked-release of ³H-DA from the striatum in vitro is inhibited by D-2 receptor agonists, but not by a D-1 receptor agonist (6, 7) and suggested that the release-inhibiting DA autoreceptors are also the D-2 type.

Taking these results into consideration, the D-1 type of autoreceptors located on dopaminergic nerve terminals, if any, appears not to be involved in the regulation of DA synthesis. In our preliminary experiment, we have shown an involvement of postsynaptic D-1 receptors in the regulation mediated by the striato-nigral feedback loop of DA release from the striatum studied by the in vivo dialysis method (H. Watanabe et al. unpublished observation). The functional role of D-1 receptors is not known, but the receptors seem to have some relation to the mobilization of a second messenger system including A kinase through the activation of adenylate cyclase (21).

Acknowledgement: We are indebted to Dr. A. Barnett (Schering Corp.) for the gift of SCH 23390 and to Dr. S. Usuda (Yamanouchi Seiyaku) for YM-09151-2.

References


